#### 1 FULL TITLE

- 2 Effectiveness of integrating cervical cancer prevention strategies into HIV care
- 3 programmes: A mixed-methods systematic review protocol.

#### 4 SHORT TITLE

5 Integrating cervical cancer prevention strategies and HIV care services.

6

- 7 Kimeshnee Govindsamy<sup>1,2\*</sup>, Susanne Noll<sup>2</sup>, Ntombifuthi Blose<sup>3</sup>, Edina Amponsah-Dacosta<sup>2</sup>
- 8 <sup>1</sup> Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine,
- 9 University of Cape Town, Western Cape, South Africa.
- <sup>2</sup> Vaccines for Africa Initiative (VACFA), Faculty of Health Sciences, School of Public
- 11 Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
- 12 <sup>3</sup> Health Systems Trust, Durban, South Africa
- 13 \*Corresponding author
- 14 Email: <u>GVNKIM019@myuct.ac.za</u>
- 15
- 16 **Funding:** No financial support will be required for this review.
- 17 **Competing interests:** The authors have declared that no competing interests exist.
- 18 **Data availability:** No datasets will be generated or analysed for this systematic review
- 19 protocol. All relevant data from this study will be made available upon study completion.

20

21

# 22 Abstract

## 23 Introduction

24	Cervical cancer, which is the fourth most frequently diagnosed cancer among women
25	globally, remains a significant health burden despite being preventable and treatable,
26	exposing gaps in accessing prevention and control services. Adolescent girls and young
27	women (AGYW) face heightened risk of persistent HPV infection, a primary cause of
28	cervical cancer. The overlap of cervical cancer and HIV exacerbates public health challenges,
29	especially in resource-limited areas, urging intensified efforts in bolstering prevention and
30	control measures. Integrating HPV vaccination, cervical cancer screening, treatment of
31	precancerous lesions and educational interventions into HIV care programs shows promise in
32	effectively addressing this dual burden.

## 33 Methods

To evaluate the effectiveness of integrating cervical cancer prevention strategies within HIV 34 35 care programs, a mixed-methods systematic review will be conducted. A comprehensive 36 Boolean search for literature published between 2006 to present and indexed in PubMed, 37 Cochrane Library, EBSCO Host, Web of Science, Scopus, and Google Scholar will be 38 conducted, without imposing any language restrictions. This review will be conducted in 39 alignment with the Joanna Briggs guidelines on systematic reviews together with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 40 41 Data from eligible studies will be extracted and synthesized, and their quality assessed.

42

43

## **Discussion**

45	There is limited understanding of the effectiveness of integrating cervical cancer prevention
46	and HIV care in the real-world setting. While some studies touch on integration, focus tends
47	to be on cervical cancer screening alone, neglecting vaccination, treatment of precancerous
48	lesions, and education programs. Previous reviews on this focus are outdated, surpassing six
49	years. This systematic review aims to fill these evidence gaps by thoroughly evaluating the
50	challenges and opportunities associated with integrating the full complement of HPV
51	prevention strategies and HIV care programs. The anticipated findings could enhance service
52	delivery models aimed at reducing cervical cancer incidence and mortality among AGYW
53	living with HIV.
54	Trial registration
55	Systematic review registration: PROSPERO registration number: CRD42024535821.

#### Introduction 65

#### **Background** 66

67 Cervical cancer ranks as the fourth most frequently diagnosed cancer among women globally, 68 with current global estimates from 2022 indicating that 660 000 women are diagnosed with 69 cervical cancer and 350 000 women die from this disease annually, according to the World 70 Health Organization (WHO) [1]. Persistent infection with the Human Papillomavirus (HPV) 71 following sexual transmission is the primary sufficient cause of cervical cancer [2]. 72 Furthermore, cervical cancer is the most common HPV-related disease [2]. Most HPV 73 infections resolve spontaneously and do not cause symptomatic disease. However, persistent 74 infection with specific high-risk HPV types (most frequently HPV types 16 and 18) may lead 75 to pre-cancerous lesions and if untreated these lesions may progress to invasive cervical 76 cancer [2]. According to Okunade [2] approximately 99.7% of cervical cancer cases are 77 caused by persistent high-risk HPV infection. HPV is estimated to infect approximately 291 78 million women globally, with a significantly higher prevalence among women under the age 79 of 25 years [3]. 80 There are significant disparities in the prevalence of cervical cancer globally which highlights 81 variations in accessibility, coverage, and quality of preventative and control measures as well 82

as the prevalence of risk factors for cervical cancer. More than 85% of cervical cancer cases

83 and deaths occur in low- and middle-income countries (LMICs) where these measures are

84 suboptimal whilst the prevalence of risk factors are usually higher [4]. This inequality gap

85 continues to widen, as substantial declines in cervical cancer incidence rates have been

86 observed in high-income countries (HICs) with some nations even forecasted to be

- 87 progressing toward the goal of cervical cancer elimination in the coming decades [5]. This
- 88 can be attributed to the effectiveness of routine cervical cancer prevention programs in these

89 regions. In contrast, in certain sub-Saharan African regions and in several European and 90 western Asian countries, rates have either increased or remained relatively stable at elevated 91 levels [5]. This is attributed to the suboptimal provision and utilization of prevention 92 programs in these settings. 93 Although HPV is the underlying sufficient cause of cervical cancer there are other risk factors 94 associated with this disease which include smoking, increased parity, long-term use of oral 95 contraceptives as well as infection with human immunodeficiency virus (HIV) [2]. Studies have shown that women who are HIV-positive face a six-fold increased risk of developing 96 97 cervical cancer compared to those without HIV, which further exacerbates the burden of 98 cervical cancer [5]. This heightened risk stems from a multifaceted interplay of biological and 99 societal factors. Among these are the direct impact of HIV on the immune regulation of HPV, 100 accelerated disease advancement in HIV-positive women, extended life expectancy due to 101 antiretroviral therapy, and obstacles such as stigma, poverty, and gender-related barriers that 102 hinder women from accessing timely care [4]. Compelling evidence indicates that women 103 infected with HIV face an elevated risk of persistent infection with multiple types of HPV at 104 an early age, specifically between the ages of 13 and 18 years, which contributes to an 105 increased likelihood of developing cervical cancer at a younger age [3]. This dual burden of 106 HPV and HIV poses a complex challenge to healthcare systems worldwide, especially among 107 adolescent girls and young women (AGYW) living with HIV. 108 Cervical cancer can be prevented, treated, and ultimately eliminated as a public health 109 concern through primary, secondary, and tertiary prevention measures. These prevention 110 strategies differ among females living without and with HIV as outlined in Fig 1, as per the 111 WHO guidelines [6]. Primary prevention measures include HPV vaccination and educational 112 interventions that create awareness related to cervical cancer risks and prevention and control

113	strategies. Secondary prevention includes cervical cancer screening and treatment of
114	precancerous lesions. Tertiary prevention includes the treatment of invasive cancer.

115

116 Fig 1. Summary of cervical cancer prevention strategies as per WHO guidelines [6].

117

#### 118 **Primary prevention**

119 Prophylactic HPV vaccination has been regarded as the most effective long-term strategy for 120 preventing HPV infection, cervical cancer and other cancers associated with HPV [4]. HPV 121 vaccines are most effective if administered prior to HPV-exposure and therefore is primarily 122 targeted to adolescent girls (9-14 years of age), prior to sexual debut [7]. The first HPV 123 vaccine was licensed in 2006 and currently there are six licensed prophylactic vaccines 124 available, all of which are recommended for global use by the WHO [7]. These include three 125 bivalent vaccines, two quadrivalent vaccines and one nonvalent vaccine [4]. HPV vaccines 126 are designed to prevent over 95% of HPV infections caused by the common high-risk HPV 127 types 16 and 18 as well as some cross protection against other less common HPV types that 128 can cause cervical cancer [1]. Vaccination is a powerful preventative strategy as it targets the 129 underlying cause and moreover widespread vaccination creates herd immunity, benefiting 130 even those who cannot receive vaccines. According to WHO recommendations, females aged 131 9-20 years should receive one- or two-dose schedules and females 21 years and older should 132 receive two-doses with a six- month interval [7]. Females living with HIV at all ages should 133 receive three doses (or two doses if feasible) [7]. The high prevalence of HPV infections in 134 HIV positive females emphasizes how important it is to vaccinate this population. HPV 135 vaccines are a safe and effective tool that when combined with other cervical cancer

136 prevention strategies can significantly reduce the incidence of cervical cancer and its

#### 137 associated mortality.

138	Educational interventions encompass health education initiatives that are designed to enhance
139	an individual's understanding and awareness of health-related matters, in this instance
140	matters relating to cervical cancer prevention strategies, which ultimately would lead to a
141	positive change in their behaviour [8]. These interventions play a crucial role in creating
142	awareness and imparting knowledge on the importance of cervical cancer prevention
143	strategies and risks. In addition, sexual and reproductive education, tailored to age and
144	culture, that promotes safer sexual practices also aids in creating awareness and potential
145	behavioural changes. In providing the necessary information females are empowered to make
146	informed decisions about their health, seek HPV vaccination services and timely screening,
147	as well as adopt proactive measures and ultimately reduce their risk of developing cervical
148	cancer.

#### 149 Secondary prevention

150 To prevent cervical cancer females can undergo various cervical screening tests to detect 151 precancerous cells and thereafter receive the appropriate pre-treatment to reduce the risk of 152 progression to invasive cervical cancer. The conventional approach for screening involves 153 cytology screening (conventional or liquid based), commonly known as Papanicoloau (Pap) 154 test or pap smear [9]. Positive cytology results lead to confirmation through colposcopy, and 155 subsequent biopsies of suspicious lesions for histologically confirmed diagnosis [9]. Over the 156 past 15 years, additional screening strategies have been introduced including visual 157 inspection with acetic acid (VIA) and molecular tests such as high-risk HPV DNA testing [9]. 158 In 2021 the WHO recommended HPV-DNA detection as the primary screening method 159 particularly for females living with HIV [6]. The WHO identifies females living without HIV

160	in the age group 30-49 years as a priority for screening and should be screened every five to
161	ten years with a pap smear, VIA technique or HPV-DNA testing [6]. For females living with
162	HIV, those aged 25-49 years are identified as a priority group and should be screened every
163	three to five years preferably with HPV-DNA testing or other screening tests as available [6].
164	After the age of 50 years the WHO suggests screening is stopped after two consecutive
165	negative screening results in females living with and without HIV [6]. More recently newer
166	techniques have been developed: other molecular tests such as those relying on HPV
167	messenger ribonucleic acid (mRNA), oncoprotein detection or DNA methylation; more
168	objective assessments conducted on cytological samples such as p16/Ki67 dual staining; and
169	enhanced visual inspection tests utilizing artificial intelligence/ machine learning platforms
170	such as automated visual evaluation of digital images [6].
171	In resource-limited settings, the predominant approach for treatment of cervical abnormalities
172	is tissue ablation techniques such as cryotherapy or thermal ablation [10]. Ideally, if the
173	patient qualifies for ablative treatment, it should be performed immediately during the same
174	visit as the positive screening test (single-visit approach). However, at times this may not be
175	feasible in some healthcare facilities and therefore a second visit is required (multiple-visit
176	approach). For women who are not eligible for ablation or in HICs the main approach for
177	treatment involves the excision of histologically confirmed cervical abnormalities [10].
178	Excisional treatment options include loop electrosurgical excision (LEEP), large loop
179	excision of the transformation zone (Lletz) or cone excision [10].
180	The WHO recommends two approaches to screening and treatment namely, the "screen-and-
181	treat" and the "screen triage and treat" approach [6] In the "screen-and-treat" approach
182	treatment is administered to females solely based on a positive primary screening test (which
183	means there is no secondary screening test and no histopathological diagnosis) [6]. In the
100	"server trices and treat" and the treatment of the initial and the first server trices and treat"
184	screen, mage and treat approach the treatment decision is based on a positive result from

Page 8 of 30

the initial screening test, followed by a positive outcome in a subsequent test (referred to as a "triage" test), with or without histologically confirmed diagnosis [6]. For females in the general population, the WHO recommends HPV DNA detection as the screening method in a "screen-and-treat" or "screen, triage and treat" approach starting at the age of 30 years with regular screening every five to ten years [6]. For females living with HIV, it is recommended that HPV DNA detection be used in a "screen, triage and treat" approach only starting at the age of 25 years with regular screening every three to five years [6].

192 Despite the development and implementation of cervical cancer prevention strategies this 193 disease continues to be a public health concern, particularly in LMICs. As a result of this in 194 2020 the WHO introduced a "global strategy" to accelerate the elimination of cervical cancer 195 [6]. This strategy proposes the following targets: 90% of adolescent girls globally should be 196 vaccinated against HPV; 70% of women should undergo HPV screening and 90% of women 197 diagnosed with cervical cancer should receive suitable follow-up treatment [6]. The aim of 198 this global strategy is to reduce the incidence of cervical cancer to below a threshold of 4 199 cases per 100 000 women-years in every country [11]. Meeting these objectives set out by the 200 WHO requires reconsideration of existing strategies to accelerate the adoption of HPV 201 vaccination, cervical cancer screening and timely treatment of precancerous lesions, whilst 202 optimizing rational resource allocation and use. The WHO advocates for the integration of 203 these prevention strategies in other healthcare systems to further enhance its effectiveness 204 [12].

205 There has been a growing interest in integrating cervical cancer prevention strategies into

HIV care programs [13]. Such integration can potentially improve access to cervical cancer

screening, early detection, and pre-treatment services for AGYW living with HIV.

208 Additionally, it may offer opportunities for the efficient utilization of established healthcare

209 resources and strengthen the health system's capacity to address both HIV and cervical

210	cancer. Integrated healthcare approaches aim to leverage existing HIV care infrastructure to
211	provide cervical cancer preventative services, which can encompass the full complement of
212	prevention strategies. The integration not only streamlines healthcare delivery but also
213	capitalizes on the regular contact that AGYW living with HIV have with healthcare
214	providers. Supporting evidence highlighting the feasibility and outcomes of such integration
215	programs has been published. For instance, Mwanahamuntu et al., [14] conducted a study on
216	the integration of cervical cancer prevention services into HIV care services in Zambia and
217	reported that over the course of 2.5 years more than 20 000 women had undergone cervical
218	cancer screening following integration. Furthermore, studies conducted in Kenya,
219	Mozambique and Botswana have reported cervical cancer screening within HIV care services
220	to be feasible, acceptable, and effective [15–17].
221	Despite the potential benefits of integrating cervical cancer prevention and HIV care, there is
222	still a limited understanding of its effectiveness in the real-world setting. As such, it is
223	important to systematically assess the effectiveness of integrating such programs across
224	various contexts.
225	This systematic review seeks to comprehensively assess existing evidence, by employing a
226	mixed methods approach, to provide a holistic understanding of the outcomes and
227	implications of integrating cervical cancer prevention strategies into HIV care programs. This
228	review will delve into the uptake of HPV vaccination, cervical cancer screening,
229	precancerous treatment, and educational interventions aimed at enhancing personal urgency
230	and positive behavioural change. In addition, we will describe the knowledge, awareness, and
231	willingness of AGYW living with HIV with regards to utilizing and adhering to these
232	strategies following integration into existing HIV care programs. Given the increasing global
233	burden of cervical cancer, the continued burden of HIV, and the increased risk of HPV
234	infections in AGYW living with HIV, this review will hold significant relevance and urgency

for public health initiatives aimed at improving the health and well-being of AGYW livingwith HIV as well as reducing the incidence and mortality rates of cervical cancer.

237

## 238 Rationale for the review

239 Cervical cancer is the fourth most common cancer among women globally, despite it being a 240 preventable and curable health issue through universal access to effective cervical cancer 241 prevention and control programs. AGYW living with HIV are a population of particular 242 concern as they are at an increased risk of persistent infection with multiple types of HPV. 243 The co-occurrence of cervical cancer and HIV represents a significant public health 244 challenge, particularly in resource-limited settings and requires more effort to be placed on 245 improving current cervical cancer prevention and control measures. Cervical cancer 246 prevention strategies should encompass multidisciplinary approaches that include HPV 247 vaccination, screening, precancerous treatment, and educational interventions. Utilising 248 existing HIV care programmes as a means of integrating cervical cancer prevention strategies 249 into HIV routine care provides an effective way for improving cervical cancer prevention for 250 the most at-risk population and should be prioritised. Existing literature primarily focuses on 251 isolated aspects of either HIV care or cervical cancer prevention, or some but not all 252 preventative strategies, thus leaving a fragmented understanding of the holistic benefits of 253 integrating these public health concerns. Studies have considered integration of these 254 programs [15–17], although, more focus is placed on cervical cancer screening as a 255 prevention strategy as opposed to comprehensive approach that includes vaccination, 256 education, and pre-treatment. Moreover, the search end dates of these reviews are outdated -, 257 being more than six years old- and do not consider recent recommendations and 258 advancements in the field. This review aims to provide a comprehensive assessment of the

259	effectiveness, knowledge, awareness, and willingness among AGYW living with HIV,
260	related to integrating cervical cancer prevention strategies, which includes vaccination,
261	screening, precancerous treatment, and educational interventions, into existing HIV care
262	programs. A mixed methods systematic review is an ideal research design for this study as it
263	allows for an overall examination of both quantitative and qualitative data. The quantitative
264	evidence will provide insights into the effectiveness of the integration strategy, whilst the
265	qualitative evidence can shed light on the knowledge, awareness, and willingness of AGYW
266	living with HIV. Findings from this review will have the potential to reform current policy
267	and practice, thereby contributing to improving health outcomes for AGYW living with HIV
268	and reduce cervical cancer incidence and mortality.

269

# 270 Research aims and objectives

## 271 Aim

To describe the effectiveness of integrating cervical cancer prevention strategies into existingHIV care programs.

## 274 **Objectives**

- To identify and describe integration models for cervical cancer prevention strategies
   and HIV care programs.
- 277 2. To assess the effectiveness of integrating cervical cancer prevention strategies into
- existing HIV care programs.

279	2.1 To assess the uptake of HPV vaccination, cervical cancer screening, precancerous
280	treatment, and educational interventions among AGYW living with HIV
281	following integration into existing HIV care programs.
282	2.2 To assess the knowledge, awareness, and willingness of AGYW living with HIV
283	to utilise and adhere to cervical cancer prevention strategies following integration
284	into existing HIV care programs.

285

# 286 Methods

007	A 1 · ·	1 11 1 1 11		· · · · · ·
287	A comprehensive mixed	i methods review that	t evaluates primary	studies employing
-01	ri comprenensive mine.	incentous review end	e e culdados printary	studies employing

288 qualitative, quantitative, and mixed methods will be conducted in alignment with the Joanna

289 Briggs guidelines on mixed methods systematic reviews together with the Preferred

290 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18,19].

291 The protocol for this review was developed in accordance with the PRISMA-Protocol

292 (PRISMA-P) guidelines and checklist (S1 Checklist. PRISMA-P 2015 checklist.) and is

registered with the International Prospective Register of Systematic Reviews (PROSPERO)

(ID: CRD42024535821), any changes to the published record will be reported [20]. The

proposed timeline for this review is February 2024 to February 2025.

296

297

298

# 299 Eligibility Criteria

#### 300 Inclusion Criteria

301	1.	All primary research studies (including those with quantitative, qualitative, and mixed
302		methods research designs) reporting findings on the effectiveness, knowledge,
303		awareness, and willingness related to integrating cervical cancer prevention strategies
304		(vaccination, education, screening, treatment of precancerous lesions, and educational
305		interventions) into existing HIV care services will be considered. This includes all
306		observational studies (cross-sectional and cohort), interventional studies (single-arm
307		intervention studies, randomised control trials, cluster randomised control trials,
308		cross-over trials, and non-randomised control trials) and qualitative studies
309		(interviews, surveys, focus groups, ethnography, phenomenology, grounded theory
310		studies and qualitative process evaluations).
311	2.	The target population for this review are AGYW living with HIV, which according to
312		the WHO are females aged between 9 and 25 years of age. Therefore, only studies
313		that include females within this age group living with HIV will be included.
314	3.	Only studies published after 2006 will be considered, since the first commercially
315		available prophylactic HPV vaccine was approved in this year.
316	4.	This systematic review has global significance that aims to address universal
317		challenges affecting cervical cancer research on a global scale and therefore there will
318		be no geographical limits placed on search strategy.
319	5.	We will not enforce any limitations on the language of publication. Instead, we will
320		facilitate the translation of any potentially relevant publications into English to ensure
321		their inclusion in the selection process and facilitate data extraction.

322

## 323 Exclusion criteria

324	1.	Studies that exclusively focus on AGYW living without HIV or that do not clearly
325		specify the age and HIV status of the study participants will be excluded as this
326		review focuses primarily on AGYW living with HIV.
327	2.	Studies that include females younger the 9 or older than 25 years of age as this does
328		not align with the target population for this review.
329	3.	Studies that evaluate the integration of cervical cancer prevention strategies into
330		programs other than HIV care services will not be considered.
331	4.	Studies published prior to 2006 will be excluded from this review as prophylactic
332		HPV vaccines were not approved or commercially available at the time.
333	5.	This review will exclude all other review studies, modelling studies, evidence
334		synthesis studies, case studies, case series, case reports and conference proceedings.
335		

## 336 Outcomes

337	1.	A description of models used to integrate cervical cancer prevention strategies with
338		existing HIV care programs will be identified and described.
339	2.	The effectiveness of integrating cervical cancer prevention strategies into existing
340		HIV care programs will be assessed in terms of the following outcomes:
341		2.1 The uptake of HPV vaccination, cervical cancer screening, precancerous
342		treatment, and educational interventions by AGYW living with HIV following
343		integration.
344		2.2 The knowledge, awareness, and willingness of AGYW living with HIV to utilise
345		and adhere to cervical cancer prevention strategies following integration.

### 346 Search strategy

347	A search strategy will be developed by one of the authors (KG) together with an information
348	specialist (SN). A comprehensive literature search will be performed to enable capturing of as
349	many relevant articles as possible based on the inclusion and exclusion criteria outlined. The
350	following online electronic databases will be searched: PubMed, Cochrane Central Library,
351	EBSCO Host (Academic Search Premier, Africa-Wide Information, Cumulative Index to
352	Nursing and Allied Health Literature [CINAHL], Health Source - Consumer Edition, Health
353	Source: Nursing/Academic Edition, APA PsycArticles, APA PsycInfo), Web of Science,
354	Scopus, and Google Scholar. Key words, medical subject headings (MeSH) and text words
355	related to the themes; cervical cancer, HIV, prevention strategies and integration will be
356	developed and then combined in the search strategy using Boolean operators, after which
357	eligible articles will be identified. The search will be modified and applied to each electronic
358	database (S1 Appendix. Database literature search strategy.). A standardized report template
359	that will aid in keeping a record of all electronic databases searched, the search terms used
360	and the total count of search results for each database will be developed and maintained.
361	Reference lists of relevant studies will be searched for further articles in case they were
362	missed during the primary searches. No geographical or language limitations will be applied.

363

## 364 Study selection

All publications identified from the electronic database searches will be downloaded into a
reference manager program, Zotero [21], and imported into a web-based platform called
Rayyan for deduplication and screening [22]. Two authors (KG and NB) will independently
screen articles by title and abstract and then full text articles screened for inclusion against

369	the eligibility criteria. Reasons for exclusion of full text studies that do not meet the inclusion
370	criteria will be recorded and reported in a table. Where the same study, using the same
371	sample and methods, has been presented in different reports, we will collate these reports so
372	that each study (rather than each report) is the unit of interest in our review to avoid over
373	representation of datasets in each study in the systematic review results. Oversight of the
374	study selection process will be provided by a third author (EA-D). Any disagreements that
375	arise between the two authors (KG and NB) at any stage of the study selection process will be
376	resolved through discussion and will involve a third author (EA-D) if necessary. A PRISMA
377	flow diagram will be used to present the selection process and results of the search [19].

378

### 379 Data extraction and management

380 Data extraction will be performed using piloted extraction forms by two authors (KG and 381 NB) to ensure consistency across included studies. Standardised data extraction forms will be 382 designed using Microsoft excel file (Version 2402) and used to record extracted data from 383 included publications. Individual forms will be created and used to record quantitative and 384 qualitative data (S2 Appendix. Data extraction form) extracted from quantitative, qualitative, 385 and mixed method studies. A pilot data extraction process with a draft extraction form will be 386 performed on approximately 10 articles to determine if all relevant information is being 387 captured.

- 388 The Cochrane Handbook will be used to provide guidance for the inclusion of cluster389 randomised control trials in this review [23].
- 390 Two authors (KG and NB) will extract the data, and a third author (EA-D) will cross  $\Box$  check
- 391 the data to ensure that all relevant data has been extracted. Any disagreements between KG

and NB will be resolved by discussion. A third author (EA-D) will be involved to resolve any

393 outstanding disagreement as necessary.

394

## 395 Dealing with missing data

396 Study authors will be contacted via email regarding any unreported data or to seek

397 clarification on study methods. Should the data remain unavailable, the data at hand will be

analysed and the significance of any missing data will be discussed among authors (KG, NB

and EA-D). Authors will then deliberate on the most suitable method for dealing with the

400 missing data as per guidelines outlined in the Cochrane Handbook [24].

401

### 402 Methodological quality assessment

All included studies (quantitative, qualitative, and mixed methods) will be assessed for
methodological quality independently and in duplicate by two authors (KG and NB). Any
disagreements will be resolved by discussion or by involving a third author (EA-D) if
necessary.

#### 407 **Quantitative studies**

408 To assess randomised controlled trials (RCTs) included in this review we plan to utilise the

409 Cochrane risk of bias tool (ROB-2) [25]. This tool evaluates selection, performance,

410 detection, attrition, reporting and additional sources of bias allowing us to categorise each of

411 the included studies as having low, moderate, or high risk of bias. A summary of the

412 assessment of each study with the overall judgement will be recorded and tabulated.

413	Non-randomised controlled trials (non RCTs) will be critically appraised using the
414	Newcastle-Ottawa Scale (NOS) [26]. The NOS uses a star system for each included non
415	RCT, which entails scoring stars based on a specific criterion. The overall quality of each
416	study will be interpreted based on the total number of stars awarded. A comprehensive
417	summary of all the assessments conducted, along with an overall judgement, will be recorded
418	and tabulated.

#### 419 **Qualitative studies**

- 420 The Critical Appraisal Skills Programme (CASP) quality assessment tool for qualitative
- 421 studies will be applied to determine the rigour of qualitative methods used in included
- 422 studies. The CASP tool will be used to examine the quality of a study in relation to 10
- 423 questions about research aims, appropriateness of methodology and design, recruitment
- 424 strategy, data collection, researcher reflexivity, consideration of ethical issues, data analysis,
- statement of finding and the value of the research [27].
- 426 Mixed methods studies
- 427 The Mixed Methods Appraisal Tool (MMAT) will be applied to assess the risk of bias for
- 428 mixed method studies [28]. The following criteria will be used to assess the risk of bias:
- 429 1. Is there an adequate rationale for using a mixed methods design to address the430 research question?
- 431 2. Are the different components of the study effectively integrated to answer the432 research question?
- 433 3. Are the outputs of the integration of qualitative and quantitative components434 adequately addressed?
- 435 4. Are divergences and inconsistencies between quantitative and qualitative results436 adequately addressed?

437 5. Do the different components of the study adhere to the quality criteria of each

438 tradition of the methods involved?

439

## 440 Unit of analysis

441 The unit of analysis for the quantitative component of this review will be primarily at the

442 individual level. Studies that will be selected for inclusion in this review will assess the

443 effectiveness of integrating cervical cancer prevention strategies into HIV care services in

444 improving the uptake of these strategies by AGYW living with HIV globally. Key

epidemiological measures such as changes in the incidence, mortality, or prevalence of

446 cervical cancer as well as utilisation of cervical cancer prevention services and rates thereof

- 447 will be analysed at an individual level.
- 448 The unit of analysis for the qualitative component will be thematic. Qualitative data from
- included studies will be analysed to identify common themes related to the effectiveness of
- 450 integrating cervical cancer prevention strategies into HIV care services. Themes related to the
- 451 knowledge, awareness, and willingness of AGYW living with HIV to utilise these services

452 following integration will be analysed at an individual level.

453

#### 454 Data synthesis

#### 455 **Quantitative studies**

456 The findings from the included quantitative studies will be narratively summarised and

457 graphically illustrated [29]. Study results will be expressed as either numeric results or

458 measures of association, with their associated variation and confidence intervals. The

459	magnitude of heterogeneity between the included studies will then be assessed quantitatively
460	using the $I^2$ statistic [30]. $I^2$ values will be interpreted as follows: 0 to 40% might not be
461	important; 30 to 60% may represent moderate heterogeneity; 50 to 90% may represent
462	substantial heterogeneity and 75 to 100% represents considerable heterogeneity [30]. The
463	significance of heterogeneity will be determined by the p-value as outlined in the Cochrane
464	Handbook [30]. For studies with moderate to significant heterogeneity, a random effects
465	model will be used to obtain a pooled estimate of the outcome. If heterogeneity is between 0
466	to 40% a random effects model will also be used. In this instance, the random effects model
467	will account for our lack of knowledge about why real, or apparent, intervention effects differ
468	by considering the differences as if they were random [30].
469	Random effects models for meta-analysis will be performed using Review Manager software
470	(RevMan 2020, V.5.4.1). If the heterogeneity detected is significantly high, a subgroup
471	analysis will be performed to detect the possible sources [31]. A funnel plot will be used to
472	assess for publication bias using R software (R Studio version 2023.03.0+386). Asymmetric
473	distribution of the plot will indicate potential publication bias [32]. In addition, to statistically
474	confirm whether the asymmetry is significant or not the Begg and Egger's test will be
475	performed using R software, where a p-value less than 0.05 indicates asymmetry and
476	potential publication bias (R Studio version 2023.03.0+386) [32].

## 477 Qualitative studies

For the qualitative analysis thematic synthesis will be used to combine the findings of studies that describe the knowledge, awareness, and willingness of AGYW living with HIV to utilise and adhere to cervical cancer prevention strategies following integration [33]. The findings of included qualitative studies will be examined against the aims of this review, recurring patterns will be identified, and the qualitative data patterns will be interpreted by developing

500	studies to check that we have extracted all data relevant to the findings.
499	will be shared with the third author (EA-D) to review. Finally, we will re-read the included
498	synthesised from the data that have been given the same codes across the studies. Findings
497	Data extraction will be verified by a third author (EA-D). Review findings will then be
496	or not. This process will continue until they have extracted data from all the included articles.
495	authors (KG and NB) will revisit articles already coded to determine if the new codes apply
494	conducted (KG, NB and EA-D) and the coding list will be amended accordingly. Two
493	codes arise during the analysis process, a discussion among the three authors will be
492	Relevant findings, reported anywhere in the primary qualitative studies, will be coded. If new
491	be coded line-by-line using the agreed coding framework, adding new codes as necessary.
490	from the data and agree on a preliminary coding framework. The remaining studies will then
489	another. The three authors (KG, NB and EA-D) will subsequently discuss the codes emerging
488	additional articles to determine if and how well the concepts translate from one study to
487	the "free" codes, develop an initial coding list, and independently test this list on two
486	article. The two authors (KG and NB) will subsequently discuss, with a third author (EA-D),
485	"line-by-line" coding according to the content and meaning of the relevant findings of the
484	and used as a starting point to build a coding list. Two authors (KG and NB) will conduct
483	a coding framework. One article that closely answers the review objectives will be selected

Following the synthesis of quantitative and qualitative data independently, they will be
combined using the methods and suggestions provided in the Cochrane Handbook [34].
According to the Johanna Briggs guidelines on data synthesis and integration for mixed
method reviews if the research question can be addressed by quantitative and qualitative
research designs a convergent integrated approach will be followed [35]. However, if the

507 review aims to explore various aspects or dimensions of a particular phenomenon of interest

the convergent segregated approach will be followed [35].

509

#### 510 Sensitivity Analysis

511 To ensure the robustness and reliability of the findings of this review a sensitivity analysis

512 will be conducted to assess the impact of the various methodological decisions on the results

513 of this review and will be performed on both quantitative and qualitative components. The

514 domains that will be considered include the quality of the included studies, sample size and

the meta-analysis technique applied. If results remain consistent across the different analyses,

the results can be considered robust as even with different decisions they remain the

517 same/similar. If the results differ across sensitivity analyses, this is an indication that the

result may need to be interpreted with caution [35].

519

## 520 Assessment of quality of evidence

#### 521 **Quantitative studies**

522 The quality of evidence for primary quantitative outcomes will be evaluated using the five

523 Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria:

risk of bias, consistency of effect, imprecision, indirectness, and publication bias [36]. To

525 facilitate this process, we will utilize GRADEpro GDT software and include footnotes to

- 526 elucidate any determinations made to downgrade the quality of evidence. We will use the
- 527 study design of each included study as a determining factor of whether to upgrade (i.e.
- 528 observational studies) or downgrade (i.e. RCTs) the quality of evidence.

529	An assessment of each outcome will be presented in a GRADE Evidence Profile. Two
530	authors (KG and NB) will detail the number of studies, the number of participants, and the
531	numerical result of the meta-analysis for each outcome. The effects of interventions on the
532	outcomes included in the GRADE Evidence Profiles will be interpreted according to
533	magnitude of effect and certainty of the evidence, using GRADE guidance on informative
534	statements to combine size and certainty of an effect [36]. If meta-analysis is unsuitable or
535	units of analysis are incomparable, results will be presented in a narrative 'Summary of
536	findings' table format, with a recognition of the imprecision in evidence due to the absence of
537	a quantitative effect measure [37]. This process will be reviewed by a third author (EA-D).
538	Qualitative studies
539	To evaluate the confidence in synthesized qualitative findings, the Grades of
539 540	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence
539 540 541	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence from Qualitative Reviews (CERQual) approach will be used [38]. This approach
539 540 541 542	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence from Qualitative Reviews (CERQual) approach will be used [38]. This approach encompasses four key domains: methodological limitations, relevance of contributing studies
539 540 541 542 543	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence from Qualitative Reviews (CERQual) approach will be used [38]. This approach encompasses four key domains: methodological limitations, relevance of contributing studies to the research question, coherence of study findings, and adequacy of data supporting the
539 540 541 542 543 544	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence from Qualitative Reviews (CERQual) approach will be used [38]. This approach encompasses four key domains: methodological limitations, relevance of contributing studies to the research question, coherence of study findings, and adequacy of data supporting the study findings. For each outcome, two authors (KG and NB) will consolidate the findings
539 540 541 542 543 544 545	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence from Qualitative Reviews (CERQual) approach will be used [38]. This approach encompasses four key domains: methodological limitations, relevance of contributing studies to the research question, coherence of study findings, and adequacy of data supporting the study findings. For each outcome, two authors (KG and NB) will consolidate the findings from these four domains and offer rationale to elucidate any determinations made to
539 540 541 542 543 544 545 546	To evaluate the confidence in synthesized qualitative findings, the Grades of Recommendation, Assessment, Development, and Evaluation- Confidence in the Evidence from Qualitative Reviews (CERQual) approach will be used [38]. This approach encompasses four key domains: methodological limitations, relevance of contributing studies to the research question, coherence of study findings, and adequacy of data supporting the study findings. For each outcome, two authors (KG and NB) will consolidate the findings from these four domains and offer rationale to elucidate any determinations made to downgrade the quality of evidence. This process will be reviewed by a third author (EA-D).

# 548 **Discussion**

549 This review aims to address a critical gap in the existing literature by proposing a

550 comprehensive mixed-methods systematic review on the effectiveness of integrating cervical

551 cancer prevention strategies into HIV care programs. The dual burden of cervical cancer and

552 HIV presents a significant public health challenge, especially in resource-limited settings, 553 where both conditions are prevalent. There is a need to develop effective and integrated 554 approaches that comprehensively address these dual health concerns simultaneously among 555 AGYW living with HIV. The proposed research design, a mixed-methods systematic review, 556 is well-suited to capture both quantitative effectiveness measures and qualitative insights into 557 the knowledge, awareness, and willingness of AGYW living with HIV. By incorporating 558 vaccination, screening, pre-treatment and educational interventions into the assessment 559 framework, this review aims to provide a holistic understanding of the potential benefits 560 derived from the integration of prevention strategies. The strength of this review is the 561 inclusion of current and up-to-date literature. Existing studies focus on isolated elements 562 resulting in a fragmented understanding. The global search covering multiple databases 563 enhances the robustness and reliability of this review.

564

# 565 **Conclusion**

The anticipated outcomes of this systematic review could inform and improve
implementation of current comprehensive cervical cancer prevention guidelines
recommended by the WHO. Ultimately effective integration not only aligns with a holistic
approach to women's health but also contributes substantially towards improving health
outcomes for AGYW living with HIV. Reducing cervical cancer incidence and mortality can
make a meaningful impact on global public health, thus emphasizing the importance of this
systematic review.

573

574

# 575 **Ethics**

- 576 Ethics approval will not be required for this review as the work constitutes a secondary
- analysis of published research, which is already available in the public domain.

578

## 579 **Research to practice**

- 580 The review team anticipates that the findings from this proposed systematic review will
- enhance equitable access to cervical cancer prevention services, thereby promoting the
- 582 quality of life for AGYW living with HIV.

# 583 Author contributions

- 584 Conceptualization: KG, NB and EA-D
- 585 Methodology: KG, SN, NB and EA-D
- 586 Formal analysis: KG, NB and EA-D
- 587 Data curation: KG and SN
- 588 Writing (original draft and preparation): KG
- 589 Writing (review and editing): SN, NB and EA-D
- 590 Visualization: KG, NB and EA-D
- 591 Supervision: NB and EA-D
- 592 **Project administration:** KG
- 593

# 594 **References**

- Cervical cancer. [cited 26 May 2024]. Available: https://www.who.int/news-room/factsheets/detail/cervical-cancer
- 597 2. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40:
   598 602–608. doi:10.1080/01443615.2019.1634030
- Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res.
   2022;13: 200238. doi:10.1016/j.tvr.2022.200238
- 4. Williamson A-L. Recent Developments in Human Papillomavirus (HPV) Vaccinology.
  Viruses. 2023;15: 1440. doi:10.3390/v15071440
- 5. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al.
  Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob
  Health. 2021;9: e161–e169. doi:10.1016/S2214-109X(20)30459-9
- 607 6. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Second edition. Geneva: World Health Organization; 2021.
- 609 7. Human papillomavirus (HPV). [cited 26 May 2024]. Available:
  610 https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human611 papillomavirus-vaccines-(HPV)
- 8. Zhang M, Sit JWH, Chan DNS, Akingbade O, Chan CWH. Educational Interventions to
   Promote Cervical Cancer Screening among Rural Populations: A Systematic Review.
   Int J Environ Res Public Health. 2022;19: 6874. doi:10.3390/ijerph19116874
- Banerjee D, Mittal S, Mandal R, Basu P. Screening technologies for cervical cancer:
  Overview. CytoJournal. 2022;19: 23. doi:10.25259/CMAS\_03\_04\_2021
- 617 10. Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in
  618 women living with human immunodeficiency virus. CA Cancer J Clin. 2021;71: 505–
  619 526. doi:10.3322/caac.21696
- Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11:
  e197–e206. doi:10.1016/S2214-109X(22)00501-0
- Kakotkin VV, Semina EV, Zadorkina TG, Agapov MA. Prevention Strategies and Early
  Diagnosis of Cervical Cancer: Current State and Prospects. Diagnostics. 2023;13: 610.
  doi:10.3390/diagnostics13040610
- 627 13. Sigfrid L, Murphy G, Haldane V, Chuah FLH, Ong SE, Cervero-Liceras F, et al.
  628 Integrating cervical cancer with HIV healthcare services: A systematic review.
  629 Consolaro MEL, editor. PLOS ONE. 2017;12: e0181156.
- 630 doi:10.1371/journal.pone.0181156

631 632 633 634	14.	Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, et al. Advancing Cervical Cancer Prevention Initiatives in Resource-Constrained Settings: Insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med. 2011;8: e1001032. doi:10.1371/journal.pmed.1001032
635 636 637	15.	Huchko MJ, Bukusi EA, Cohen CR. Building capacity for cervical cancer screening in outpatient HIV clinics in the Nyanza province of western Kenya. Int J Gynecol Obstet. 2011;114: 106–110. doi:10.1016/j.ijgo.2011.02.009
638 639 640 641 642	16.	Moon TD, Silva Matos C, Cordoso A, Baptista AJ, Sidat M, Vermund SH. Implementation of cervical cancer screening using visual inspection with acetic acid in rural Mozambique: successes and challenges using HIV care and treatment programme investments in Zambézia Province. J Int AIDS Soc. 2012;15: 17406. doi:10.7448/IAS.15.2.17406
643 644 645 646	17.	Ramogola-Masire D, De Klerk R, Monare B, Ratshaa B, Friedman HM, Zetola NM. Cervical Cancer Prevention in HIV-Infected Women Using the "See and Treat" Approach in Botswana. JAIDS J Acquir Immune Defic Syndr. 2012;59: 308–313. doi:10.1097/QAI.0b013e3182426227
647 648 649	18.	Lizarondo L, Stern C, Carrier J, Godfrey C, Rieger K, Salmond S, et al. Mixed methods systematic reviews. In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis. JBI; 2024. doi:10.46658/JBIMES-24-07
650 651 652	19.	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; n71. doi:10.1136/bmj.n71
653 654 655	20.	PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA- P) 2015 statement. Syst Rev. 2015;4: 1. doi:10.1186/2046-4053-4-1
656	21.	Zotero   Downloads. [cited 29 May 2024]. Available: https://www.zotero.org/download/
657 658	22.	Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5: 210. doi:10.1186/s13643-016-0384-4
659 660 661	23.	Higgins JPT, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. Cochrane Handbook for Systematic Reviews of Interventions version 64. Available: https://training.cochrane.org/handbook/current/chapter-23
662 663 664 665	24.	Deeks JJ, Higgins JPT, Altman DG. Chapter 10.12: Analysing data and undertaking meta-analyses: Missing data. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Available: https://training.cochrane.org/handbook/current/chapter-10
666 667 668	25.	Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 14898. doi:10.1136/bmj.14898

669	26.	Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Losos M, et al. The Newcastle-
670		Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-
671		Analysis.

- 672 27. Long HA, French DP, Brooks JM. Optimising the value of the critical appraisal skills
  673 programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res
  674 Methods Med Health Sci. 2020;1: 31–42. doi:10.1177/2632084320947559
- 675 28. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed
  676 Methods Appraisal Tool (MMAT) version 2018 for information professionals and
  677 researchers. Educ Inf. 2018;34: 285–291. doi:10.3233/EFI-180221
- Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the
  Conduct of Narrative Synthesis in Systematic Reviews.
- 30. Deeks JJ, Higgins JPT, Altman DG. Chapter 10.10: Analysing data and undertaking
  meta-analyses: Heterogeneity. Cochrane Handbook for Systematic Reviews of
  Interventions version 6.4. Available:
- 683 https://training.cochrane.org/handbook/current/chapter-10
- 31. Deeks JJ, Higgins JPT, Altman DG. Chapter 10.11: Analysing data and undertaking
  meta-analyses: Investigating heterogeneity. Cochrane Handbook for Systematic
  Reviews of Interventions version 6.4. Available:
- 687 https://training.cochrane.org/handbook/current/chapter-10
- Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A
  step by step guide for conducting a systematic review and meta-analysis with simulation
  data. Trop Med Health. 2019;47: 46. doi:10.1186/s41182-019-0165-6
- 33. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in
  systematic reviews. BMC Med Res Methodol. 2008;8: 45. doi:10.1186/1471-2288-8-45
- Flemming K, Booth A, Hannes K, Cargo M, Noyes J. Cochrane Qualitative and
  Implementation Methods Group guidance series—paper 6: reporting guidelines for
  qualitative, implementation, and process evaluation evidence syntheses. J Clin
  Epidemiol. 2018;97: 79–85. doi:10.1016/j.jclinepi.2017.10.022
- 697 35. Aromataris E, Munn Z. JBI manual for evidence synthesis. Adelaide, Australia: Joanna
  698 Briggs Institute; 2020.
- Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines
  informative statements to communicate the findings of systematic reviews of
  interventions. J Clin Epidemiol. 2020;119: 126–135. doi:10.1016/j.jclinepi.2019.10.014
- 702 37. Chan RJ, Webster J, Marquart L. Information interventions for orienting patients and
  703 their carers to cancer care facilities. Cochrane Consumers and Communication Group,
  704 editor. Cochrane Database Syst Rev. 2011 [cited 26 May 2024].
  705 doi:10.1002/14651858.CD008273.pub2
- 38. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gülmezoglu M, et al.
  Using Qualitative Evidence in Decision Making for Health and Social Interventions: An
  Approach to Assess Confidence in Findings from Qualitative Evidence Syntheses

- 709 (GRADE-CERQual). PLOS Med. 2015;12: e1001895.
- 710 doi:10.1371/journal.pmed.1001895
- 711

# 712 Supporting information

- 713
- 714 S1 Checklist. PRISMA-P 2015 checklist.
- 715 S1 Appendix. Database literature search strategy.
- 716 S2 Appendix. Data extraction form.

#### PROPHYLACTIC HPV VACCINATION Emailes living without HIV 9-20 years: 1 or 2 dose schedule 21 years and older: 2 dose schedule with a 6 month interval Emailes living with HIV All ages: minimum 2 dose schedule or 3 dose if feasible

#### EDUCATION

 Health promotion and education of cervical cancer risks and prevention strategies
 Sexual and reproductive education



# CERVICAL CANCER SCREENING Employee the provide state of the providence of the provid

Excision and ablation techniques remales living with HIV Excision techniques